

USE OF ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1
SIGNAL INHIBITOR FOR CANCER TREATMENT

ABSTRACT

An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody to be used in combination with a PD-1 signal inhibitor for treating cancer of a subject, a pharmaceutical composition comprising the bispecific antibody, or a method for treating cancer, including administering an anti-CLDN4/anti-CD137 bispecific antibody in combination with a PD-1 signal inhibitor to a subject. Under a coculture condition of CLDN4 expressing cancer cells and T cells, the use of both an anti-CLDN4/anti-CD137 bispecific antibody and a PD-1 signal inhibitor exhibited a promoting activity on production of interferon- γ by a T cell and a cytotoxic action, and exhibited a significant antitumor activity in a CLDN4 expressing cancer cell-transplanted mice, as compared with administration of each alone. From the results, it was shown that a combination of the anti-CLDN4/anti-CD137 bispecific antibody and the PD-1 signal inhibitor is useful for treatment of CLDN4 expressing cancer.